Janmejay R. Vyas

Janmejay R. Vyas was the founder, Chairman, and Managing Director of the Dishman Group, a prominent Indian multinational in the pharmaceutical and chemical manufacturing sector.

J.R. Vyas held a bachelor's degree in chemistry from St. Xavier's College, Ahmedabad, and a bachelor's degree in Pharma & Fine Chemical Technology from the University Department of Chemical Technology (UDCT), Mumbai.

Before founding Dishman, he worked as a consultant to various pharmaceutical companies from 1974 to 1983.

The Dishman Group was established in 1983 by J.R. Vyas, who recognized the need for a company that could deliver high-quality, high-value products and services to pharmaceutical companies worldwide.

The company initially focused on research and development for manufacturing quaternary ammonium compounds (quats) and active pharmaceutical ingredients (APIs).

The first manufacturing facility was set up in Naroda, near Ahmedabad, in 1987. Significant expansion began in 1996 at the Bavla site, which is now the company’s headquarters.

Under Vyas’s leadership, Dishman evolved from a local manufacturer to a global organization, acquiring several international facilities and companies, including Carbogen Amcis AG in Switzerland (2006) and a vitamin and cholesterol business in the Netherlands (2007).

The company now operates manufacturing sites across India, Europe (Switzerland, Netherlands, France, UK), and China, serving the pharmaceutical, biopharmaceutical, healthcare, and general industries.

J.R. Vyas was credited with establishing a culture of innovation, quality, and customer-centricity at Dishman. He emphasizes the importance of people, service, and value in building lasting partnerships with global pharmaceutical firms.

His strategic vision included early recognition of the international outsourcing opportunity in pharmaceuticals, leading to Dishman’s expansion and adherence to international manufacturing standards.

Vyas had received several honors, including:

The ‘Bharatiya Udyog Ratan Award’ (2000) from the Indian Economic Development & Research Association.

The ‘Outstanding Entrepreneur’ award (1999) by the Federation of Gujarat Industries.

The ‘AMA-Atlas Dye-chem Outstanding Entrepreneur of the Year Award’ (2008) from the Ahmedabad Management Association

Shri. S.N. Desai

Shri. S.N. Desai, was a well-known personality in the Pharmaceutical Industry and IPA. He had been associated with the Pharmaceutical Industry for more than 50 years, mainly managing multi-functional activities such as Pharmaceutical Operation, Administration, and Project Management both at national and international level. Shri S. N. Desai was a double graduate from University of Bombay. Infact, he enjoyed the privilege of being the alumnus of the first batch of L. M. College of Pharmacy, Ahmedabad way back in 1949. Over the past decades, Shri Desai had contributed immensely towards the betterment of the pharmaceutical industry and had been associated with various companies like May & Baker, Pharmed, Geoffrey Manners, Zandu and Cadila Health Care. He also worked as a consultant to various companies, sharing his expertise in the areas of technical audits, up-gradation of the facilities and development of MIS activities. He had been Treasurer of Maharashtra State Branch and then subsequently took up the position of Jt. Secretary, Secretary, Vice President and President. During his long tenure with IPA Maharashtra Branch, he was instrumental in organizing low budget workshops/seminars and two Indian Pharmaceutical Congresses in Mumbai. He was associated with Indian Pharmaceutical Congress Association (IPCA) and was Hon. Jt. Secretary in 1956 and 1977, which was jointly organized for the first time with Commonwealth Pharmaceutical Association. He was also a Treasurer of IPCA for three years. Shri Desai had been a pillar of strength to IPA at National Level. He was Vice President and subsequently President of IPA during the year 1996-1998. During his Presidentship, IPA took a very positive step towards establishment of four divisions, namely industry, regulatory, education and community pharmacy. The first convention of PDA-IPA was held under his Presidentship. Shri Desai played a key role as a convener of IPA Golden Jubilee Celebrations under the Presidentship of late Shri Ramanbhai Patel. He had been awarded the IPA Fellowship. He had been an active member of Pharma Times Editorial Advisory Board and various key subcommittees formed by IPA from time to time. He had delivered lectures on technical subjects in many seminars / workshops.

Shri Desai was a committed and dedicated Professional, who had always been contributing towards the upliftment of Pharmaceutical profession and his contribution to industry and IPA was noteworthy and significant.

Dr. H.P. Tipnis

Dr. Hemchandra P. Tipnis was born on 7th July 1933 and obtained B.Sc (Tech) and M.Sc (Tech) degree from prestigious University Department of Chemical Technology (UDCT), Mumbai, M.S. from the University of California School of Pharmacy at San Francisco and Ph. D. from University of Nebraska at Lincoln, Nebraska, in pharmaceutical chemistry. He was awarded a post-doctoral research fellowship of American Heart Association.

In a career spanning over four decades, Dr. Tipnis started his career at his Alma-mater UDCT as a Reader and moved to the Bombay College of Pharmacy as its first Principal and Professor from 1971 to 1995. Dr. Tipnis made notable contributions to the growth of pharmacy education and to the Bombay College of Pharmacy in particular from its position of oblivion to the position of eminence on the national scenario.

Dr. Tipnis is a crusader and man of many firsts. He was the first to talk about and eventually sell the concept of Industry Academic collaboration to pharma industry. Dr. Tipnis convinced both multinational and Indian pharma Industry to support Bombay College of Pharmacy. History repeated itself when in 1989, Dr. Tipnis again played a crucial role in establishing the first Industry – Academia R & D collaboration to establish Vasvik research centre in the college, later in 1993 he was pioneer in establishing the first Patel Extrusion Bioavailability centre and Dr. M.K. Rangnekar Memorial Analytical Laboratory.

As a research guide, Dr. Tipnis excelled himself in many pioneering areas like QSAR, free radical scavenging compounds, plant tissue culture, natural products for insect control. But it was in the area of bioavailability and bioequivalence, that Dr. Tipnis put his stamp of national acclaim,

He pioneered the first human volunteer, blood level bioavailability studies on Indian formulations and proved that Indian Drug Formulations are on par with internationally reputed Pharma companies products. His numerous research papers on bioavailability were ultimately taken a notice of for the amendments to Drugs and Cosmetic Act as schedule Y. He served on the first committee to formulate the details of schedule Y. He also served on Pharmacy Council of India for 15 long years and did yomen service to Indian Pharmaceutical Association since 1966.

His biggest contribution has been to organize scientific programmes of IPCA in 1988, 1989, 1990 and 1991 as Scientific Convener. He brought many top scientists in pharmacy like Prof. Takeru Higuchi, Y.W. Chein, Leslie Benet, Borchardt, Arnold Beckette. J. Robinson to name a few to India. This trend that he set was later on taken by other organizations. The epoch making seminar he organized in 1985 in Delhi, when he brought the whole team of USFDA officials to India to elaborate on NDA and ANDA procedures made a tremendous impact on Indian Pharma Industry and opened doors to file ANDA applications in U.S. In 1998 again he was pivotal to organize the scientific program of the Golden Jubilee Congress in Mumbai.

He has over 180 research papers and review articles, written 10 books and produced 35 Ph.D. and over 100 Masters Graduates. Among his several research grants, PL-480 grant of USDA, Hindustan Lever grant, many CSIR, ICMR and ICAR grants top the list. But the huge funds flowing from Pharma Industry for bioequivalence studies, not only supported many research scholars but endowed Bombay College of Pharmacy with highly sophisticated analytical instruments, which made that college a highly prestigious one in the country. He won many honours like Lunsford-Richardson award (USA), Dr. G.P. Srivastava award, M.L. Khorana Memorial Award, PAMDAL Award and IDMA awards for best research papers. He was also awarded the AICTE Emeritus Professorship.

After his retirement from the college, Dr. Tipnis took up the assignment as Corporate Advisor-Pharmacy Practice, in Medicine Shoppe. Once again his pioneering spirit sprang up. He took on himself to implement Good Pharmacy Practice concept in several of the stores of Medicine Shoppe. He formulated many leaflets, educational materials, articles in news papers on patient’s understanding of taking medicines and compliance. In this crusade he gave many presentations in remote areas of Maharashtra, Gujarat, Karnataka, Kerala to introduce the concept of Community Pharmacy.

He has widely traveled the world and visited many countries including USA, Europe, Russia, Far East and recently China.

Dr. J.N. Banerjee

A man of vision, dedication and hard work, a hardcore professional and great devotee of the Indian Pharmaceutical Association, Dr. J. N. Banerjee was born on July 10, 1927. He was educated in Allahabad, Lahore and Bombay. He graduated in Pharmacy from Banaras Hindu University in 1948. Under a Fellowship from the University of Nottingham (U.K.), he worked on the Pharmacology of number of vegetable drugs and obtained his Ph.D. Degree.

He was elected a Fellow of the Royal Pharmaceutical Society of Tropical Medicine and Hygiene and a member of the British Pharmacological Society. He then joined the Swiss multinational Sandoz in Switzerland, and rose rapidly in the company to head the company as Managing Director in 1971. In 1983 JNB was appointed Adviser, Special International Projects at the Head quarters of Sandoz, and had the distinction of being Chairman of Sandoz India concurrently.

During his years in the Chemical industry JNB was intimately associated with the Organization of Pharmaceutical Producers of India as a founder member. JNB served as a member of the several expert committees appointed by the Government of Maharashtra and the Union Government

The field of education has a special place in JNB’s heart. In 1954-56, he was honorary Professor in Pharmacology at the G.S. Medical College, Bombay and an examiner in a number of Universities. He was closely connected with the Bombay College of Pharmacy since its inception and was the Chairman of the Governing Body and a member of the Board of trustees.

He has been in the forefront of the Indian Pharmaceutical Association ever since the head quarters of the IPA moved from Banaras to Bombay (1953). JNB has served as IPA Hon. Gen. Secretary for 14 years, a feat unlikely to be surpassed. He was Vice President of IPA from 1970-74 and President from 1974-76.

JNB was elected President of the Commonwealth Pharmaceutical Association at Port of Spain (Trinidad) in 1982 and completed his term successfully in 1987. He presided over the Commonwealth Pharmaceutical Conference in Nairobi (1984). During his term, he was actively involved with the WHO and the Commonwealth Secretariat in strengthening the health delivery systems in African Countries, West Indies and Malaysia. Dr. J.N. Banerjee represented the IPA on the Council of FIP for several years.

Dr. Diptish Chakravarty

Dr. Diptish Chakravarty was a Banaras-born person and an aluminus of the Banaras Hindu University, Dept. of Pharmaceutics presided the conference of 34th session of the Indian Pharmaceutical Congress held in Varanasi. After getting his B.Pharm from BHU, Dr. Chakravarty got his Master’s and Ph.D. degrees from the United States. He had been awarded the Cooper Memorial Gold Medal and the Acharya Sir P.C. Ray Gold Medal for his research work. He was Production Manager of Smith Stanistreet and later Chief Executive of Standard Pharmaceuticals from where he retired. He was the Chairman and Managing Director of West Bengal Phytochemical Development Corporation Ltd., a West Bengal Govt. enterprise.

Diptish, as he was familiarly known to his friends, had been the Hon. Gen. Secretary of the Indian Pharmaceutical Congress Association (IPCA) for nearly two decades. He had been the pivot around which the IPCA activities have been centred. He had been so closely identified with the IPCA that a wag in the profession remarked: “IPCA was Diptish and Diptish was IPCA”. Diptish retires as the IPCA President in March 1983. Dr. Chakravarthy was a former President of the IPA. He was the President of the East India Chapter of the Royal Society of Chemistry in 1982.

Dr. M.K. Raina

Born on 13th April 1944, at Srinagar, Kashmir, graduated from Jammu and Kashmir University in 1963. He graduated in Pharmacy in 1966 from Department of Pharmacy, Nagpur University, Nagpur and there after pursued M. Pharmacy course at Punjab University, Chandigarh. Soon after completing M. Pharmacy, he joined Pharmacognosy Research Laboratories of Indian Council of Medical Research (ICMR) located at Panjab University, Chandigarh. While working on the research projects, he also worked for his Ph.D program which he obtained in 1974.

In 1972 Dr. Raina joined ICMR Headquarters at New Delhi where he accomplished himself as a dedicated scientific worker and his first publication “Medicinal Plants of India” was published in 1976. He was the Convener of weekly scientific lectures at ICMR for about 4 years and looked after the production of Indian Journal of Medical Research.

Dr. Raina moved to pharma industry in 1978 and joined Ranbaxy Laboratories Ltd., New Delhi where he was responsible for setting up of facilities for development and production of Herbal and Consumer products which were introduced in the market in early 1980’s. For nearly 40 years he has been associated with leading pharma, herbal and ayurvedic drug industries and excelled in the development of pharmaceutical, herbal and cosmetic products. As Head of Dabur Research Foundation, he was responsible for setting up of Research and Development Laboratories, Pharmaceutical Division and Quality Control Laboratories for Dabur India Ltd. At Lupin Laboratories Ltd., Mumbai he set up Herbal Research Centre and was responsible for development of herbal and consumer products including their production and quality control.

His professional achievements include Member of Ayurvedic Pharmacopoeia Committee, Govt. of India for 6 years, Member Sub-committee on Herbal Drugs, Indian Pharmacopoeia for four years, Member Research Advisory Council, Central Institute of Medicinal and Aromatic Plants, Lucknow (CSIR) for six years. As Chairman of Herbal Sub-committee, Indian Drug Manufacturers Association (IDMA), Dr. Raina co-ordinated the research work at the then Regional Research Laboratories, Jammu financed by IDMA, for standardization of selected medicinal Plants. Two volumes of Indian Herbal Pharmacopoeia were published jointly by IDMA and RRL, Jammu based on the scientific work done there. Since 2007, Dr. Raina has been a Member of South Asia Expert Panel of United States Pharmacopoeia (USP) for development of Monographs on commonly used Indian Medicinal Plants for inclusion in USP. Many of these monographs have been published in USP and Herbal Medicines Compendium.

As a Consultant on Medicinal and Aromatic Projects of United Nations Industrial Development Organisation (UNIDO), UNDP, Austria, Dr. Raina successfully completed projects in Vietnam, Malawi, Uganda and Nigeria between 1993-98. As a Technical Expert on Processing of Medicinal Plants, International Union for Conservation of Natural Resources (IUCN), Switzerland, he conducted two projects in Sri Lanka in 2000-1 for preservation and propagation of important medicinal plants being used in Traditional Medicines of Sri Lanka.

After working with reputed companies like Ranbaxy, Dabur and Lupin for nearly 17 years, Dr. Raina started his own consultancy “Green Power for Mankind” in 1996. He was associated with a number of leading pharmaceutical and herbal / ayurvedic drug industries as an Advisor / Consultant for formulation development, production and quality control of herbal and cosmetic preparations. Some of these are Uttam Pharma Labs., Mumbai; Biological Evans Ltd., Hyderabad; Ajay Group, Muscat; Kisalaya Herbals, Indore; Emami Ltd., Kolkata; Quest Institute of Life Sciences (Nicholas Piramal Group), Mumbai; Charak Pharma, Mumbai; Veve Group, Albania; Arya Vaidya Pharmacy, Coimbatore; Glenmark Pharma, Mumbai; Hindustan Unilever, Mumbai. He was associated with R & D team of Biersdorf (Nivea Group), Hamburg, Germany for four years towards identification and incorporation of Ayurvedic herbs suitable for their new range of skin care and hair care products. He represented DDN Pharmaceutical Logistics, Wisconsin, USA, in India for over eight years. DDN, now known as Dohmen Life Science Services, is one of the leading logistic service provider for health care products in USA. Dr. Raina introduced a large number of Indian pharma co’s who required storage, distribution and other logistic services for marketing their generic products in USA.

He had been on the Board of Studies of S I E S Management Studies, Navi Mumbai for two years and N M I M S Pharmaceutical Management, Mumbai for four years. Also has been on Research Board of Himani Ayurvedic Foundation, Kolkata for four years. Dr. Raina served on various Technical committees of ICMR, CCRAS, DST and NMPB of Govt. of India. He delivered a large number of lectures on various topics of pharmacy and herbal drugs both in India and abroad.

Dr. Raina had contributed significantly to the growth of IPA during last 40 years of his close association. Having joined as a student member of IPA in 1965, he actively participated in the various activities of IPA from 1980. He was a Council member and later Secretary of Delhi Branch of IPA for about eight years before moving to Mumbai in 1990. At the Headquarters of IPA in Mumbai he served as a CEC Member all through and contributed to the growth of IPA with new innovative programmes. He served as General Secretary for four years and Editor Pharma Times for nearly four years. He co-ordinated the Elocution Competition among various pharmacy colleges in the country for about 3 years. He was given IPA Fellowship Award in 1999.

He had also been actively involved in the activities of Bombay College of Pharmacy (IPA – MSB) as a member of Local Managing committee, Strategic Road Mapping for NIPTE, Industrial Collaboration and Research Mobilization (ICRM), Support for National Facility for Research and Training and Fund Raising Committee for Diamond Jubilee of BCP. He also acted as Advisor for creation of Advanced Research Centre for Herbal Drug Development at BCP.

A.I. Mehta

Mr. A.I. Mehta outstanding contribution as a founder Editor of Pharma Times, feature writer, Indian Journal of Pharmacy and Chronicles of IPA and IPCA.

Mr. A.I. Mehta was born in Ahmedabad on 1.8.1926 and obtained B.Sc (Hons. with distinction) University of Bombay and later Master of Science (Pharmacy) from the University of Wisconsin (USA).

Has been external examiner at reputed Indian Universities like Bombay, Nagpur, Banaras Hindu, S.N.D.T. and V.J.T.I, Mumbai.

Worked as Management Trainee in the R & D Dept. of Burroughs Welcome Inc., U.S.A. Worked in Dept. of Pharmacology, Haffkine Inst. Bombay and Chief Analyst, Ciba Geigy of India, Mumbai.

Mr. Mehta worked as Asst. Secretary, Hon. Secretary and Hon. Treasurer of IPA. As Asst. Editor, he wrote Notes and Views (Scientific) as Notes & News (General) for 16 years. He was the founder Editor of Pharma Times and worked for nearly 19 years. Besides editing he contributed book reviews and a regular column called causerie (pen name on proton) on subjects ranging from National Budget to trivia, continued as Consultant (Editor of Pharma Times for a long time). He received a Silver Medal and Citation from the IPA on his completing 25 years with the IPA Publications at the 29th IPCA Congress held in Waltair (1978-79).

Publications – 1) Co-author of “Fifty years Crusade for Professionalism” with Dr. R.S. Baichwal, History of IPA from 1939 to 1989. 2) Co-author of History of IPCA (1949 – 1999) with Mr. V.P. Kulkarni. 3) Co-author with Dr. F.D. Bharucha of “Handbook of Microbiological Methods and Media” (Sevak Printers, Mumbai). At IPCA Congress in Varanasi presided over Analytical Chemistry session.

Is a regular contributors to Indian Drugs Manufacturers (IDMA) Bulletin column widely appreciated and entitled “What is new in the world of medicine”.

A selfless, dedicated, unassuming person who has not run after awards, positions in organizations etc. Has worked in Honorary capacity all the time. Had been a continuous member of CEC of IPA for over 50 years to date.

J B Mody

The driving force behind creating this huge India pharma giant, Shri JB Mody's roots go back to the humble background, where economic necessities overtook the need for formal education. However, a strong entrepreneurial spirit soon sowed him established a successful pharmaceutical distribution agency in North Gujarat with his siblings. But his vision was much bigger, and soon he thought that if he could sell company products, then why could he not manufacture and sell his own products.

The first step in the realization of this vision was in the form of modest family-run business, the Unique Pharmaceuticals Laboratories. His vision and values of integrity, industry, and innovation soon took a more definite and dynamic shape in the form of JB Chemicals and Pharmaceuticals that was founded on 18th December 1976.

His keen understanding of the market helped him identify the products that changed the company's fortunes and created blockbuster brands including Metrogyl, Rantac (a ranitidine-based formula), as well as Cilacar and Nicardia, a few cardiac care medicines, while his pioneering foray into the daunted Russian market yielded great success with unique brands.

Under his direction, JB Chemicals stood tall with a BSE n NSE listing with a remarkable market cap and a 4000 plus workforce with state of the art manufacturing and R&D facilities in Maharashtra and Gujarat and world-class products that offered affordable healthcare solutions across India and the world including the USA.

His determined commitment to healtheare stemmed firm desire for the betterment of society at large. Apart from nurturing his own company, he had played a significant role in shaping the overall Indian Pharmaceutical Industry in his capacity as the founder member of the Indian Drug Manufacturers' Association (IDMA), President of IDMA as well as Chairman of Chemexil.

As an ardent philanthropist his-benevolence had touched many lives for the establishment of a pharmacy college in Rajkot, a school in Bharuch, multiple hospitals in and around Gujarat to name a few, as well as in the rehabilitation of the earthquake-affected Vavaniya village in Gujarat with the reconstruction of over 200 homes and numerous women empowerment initiatives.

Amar Lulla

Amar Lulla was a key figure in the Indian pharmaceutical industry, serving as the Joint Managing Director of Cipla. He played a crucial role in expanding Cipla’s presence globally, making essential medicines more affordable and accessible, particularly in developing countries. Under his leadership, Cipla became a pioneer in producing cost-effective HIV/AIDS medications, significantly impacting global healthcare. His efforts in innovation and market expansion helped Cipla grow into one of India’s most respected pharmaceutical companies. Lulla was known for his sharp business acumen and commitment to affordable healthcare. His contributions to the industry have left a lasting legacy, ensuring that millions worldwide continue to benefit from life-saving medicines.

Mr. Samir Desai

President & Head Business Unit - Biologics and Vaccines
Zydus

B.Sc., MA, M Phil, Executive Management Program- IIM Ahmedabad.

With 37 years of Industry experience, Samir was with Zydus Lifesciences Limited for last 24 years.

Samir was leading BU Biologics as President for Zydus Lifesciences Limited covering Biologics, Vaccines, Diagnostics & specialty pharma with coverage of Hepatology, Oncology, Nephrology, Rheumatology,Gastroenterology and Orthopaedics.

Samir was an Executive Board member at Centre for Global Hepatitis Elimination & a member of various Pandemic Preparedness Initiatives. He was passionate about Patient Centricity and equitable access. Samir had published many papers in Peer Reviewed journals & was a TEDx speaker. Samir was also a frequent speaker at various Global forums. He was on the Editorial Board of several publications and had authored multiple books. Samir lead a charitable trust and had set up multiple public service projects.

Anand Chandavarkar

Anand Chandavarkar was a visionary entrepreneur who founded Fairdeal Corporation in 1936, a company that would later evolve into FDC Limited, a prominent Indian pharmaceutical firm. His ambition was to make India self-reliant in healthcare, and under his leadership, the company developed a portfolio of products that became synonymous with their categories. ​

FDC Limited specializes in various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. The company also produces active pharmaceutical ingredients and nutraceuticals, serving both domestic and international markets. ​

Anand Chandavarkar's legacy continues through the leadership of his son, Mr. Mohan Anand Chandavarkar, who serves as the Managing Director of FDC Limited. Mohan joined the company in 1958 as an apprentice in the laboratory and has been instrumental in its growth and diversification. ​

Through their dedication and strategic vision, the Chandavarkar family has significantly contributed to India's pharmaceutical industry, ensuring the availability of quality healthcare products and reinforcing the nation's self-reliance in this critical sector.

Bhai Mohan Singh

Bhai Mohan Singh (30 December 1917 – 27 March 2006) was a pioneering Indian entrepreneur, best known for transforming Ranbaxy Laboratories into one of India's largest pharmaceutical companies. Born in Rawalpindi, British India (now in Pakistan), Singh began his business career during World War II with a construction enterprise. Following the partition in 1947, he relocated to New Delhi, where he ventured into various businesses. ​

In 1952, Singh acquired Ranbaxy, a small pharmaceutical company, from his cousins Ranjit Singh and Gurbax Singh, whose names combined to form 'Ranbaxy'. Under his leadership, Ranbaxy evolved from a modest operation into a global pharmaceutical giant, known for its innovative approaches and significant contributions to the industry. ​

Singh's contributions extended beyond the pharmaceutical sector. He served as the Vice President of the New Delhi Municipal Corporation (NDMC), where his efforts in civic matters were recognized with the prestigious Padma Shri award. His dedication to industrial development, particularly in Punjab, led to the establishment of Max India Ltd, further cementing his legacy as a visionary industrialist.

Bhai Mohan Singh's journey from a partition-era entrepreneur to a titan of the pharmaceutical industry exemplifies resilience and vision, leaving an indelible mark on India's industrial landscape.

Bhaskarrao Govind Sandu

Bhaskarrao Govind Sandu was a prominent figure in the Ayurvedic pharmaceutical industry, serving as the Chairman of Sandu Pharmaceuticals. Born in 1937, he dedicated over six decades to advancing Ayurvedic medicine, significantly contributing to its growth and recognition. Under his leadership, Sandu Pharmaceuticals, a company with a legacy spanning more than 120 years, flourished and became a trusted name in the industry. ​

Throughout his tenure, Bhaskarrao Sandu was instrumental in modernizing the production processes of Ayurvedic medicines, ensuring they met contemporary standards while preserving traditional wisdom. His commitment to quality and efficacy helped the company expand its product range and reach a broader audience, both domestically and internationally.​

Beyond his corporate achievements, Sandu was known for his dedication to promoting Ayurveda as a holistic approach to health and wellness. He actively participated in various industry forums and was a respected voice advocating for the integration of Ayurvedic practices into mainstream healthcare.​

Despite extensive research, specific details regarding awards or formal recognitions bestowed upon Bhaskarrao Govind Sandu remain limited. However, his enduring impact on the Ayurvedic industry and his commitment to promoting traditional medicine stand as a testament to his contributions.

Sardar Bhupinder Singh Manhas

Sardar Bhupinder Singh Manhas was the founder of Harman Finochem and a dedicated pharma professional for the past 30 years. Under his guidance and support the company has achieved magnificent milestones. Manhas earned a master’s degree in science. Harman Finochem Ltd, has its offices in Shendra, Chhatrapati Sambhajinagar, Mumbai, and is well-known for its global presence. Manhas was a key figure in the industry, renowned for his successful endeavors and philanthropic contributions. Notably, his role in supporting the CMIA's corona fight initiative will be remembered as a significant milestone.

Manhas also held directorship positions in other notable companies, including Well Worth Medicines Pvt Ltd, Sanskar Info TV Pvt Ltd, and Idiscovery Finochem Ltd. He is survived by his wife, two sons, and grandchildren.

Desh Bandhu Gupta

Desh Bandhu Gupta (8 February 1938 – 26 June 2017) was an Indian entrepreneur and philanthropist, best known as the founder of Lupin Limited. Born in Rajasthan, he earned a master’s degree in chemistry and started his career as an associate professor before venturing into the pharmaceutical industry. In 1968, he founded Lupin with just ₹5,000, later securing a loan to establish a manufacturing facility. Under his leadership, Lupin grew into a global pharmaceutical powerhouse, especially in the U.S. and Japanese markets.

Beyond business, Gupta was dedicated to social welfare. He established the Lupin Human Welfare & Research Foundation in 1988, positively impacting millions in rural India through development programs. His contributions were widely recognized, earning him awards like the Ernst & Young Entrepreneur of the Year (2011) and Frost & Sullivan Lifetime Achievement Award (2013). In 2018, he was posthumously inducted into the CNBC TV18 India Business Leader Awards Hall of Fame.

In addition to his business achievements, Gupta was deeply committed to social welfare. In October 1988, he established the Lupin Human Welfare & Research Foundation (LHWRF) with the goal of creating a sustainable model for rural development. The foundation aimed to uplift families living below the poverty line in rural India by focusing on holistic development programs that created opportunities and infrastructure, empowering rural communities, and ensuring their inclusion in the nation's economic progress. The Lupin Foundation impacted the lives of 2.8 million people across approximately 3,500 villages in nine states, including Rajasthan, Maharashtra, Madhya Pradesh, Goa, Uttarakhand, Gujarat, Jammu, Andhra Pradesh, and Sikkim.

D. Gupta was married to Manju and resided in Mumbai. He was survived by his wife and five children: four daughters and one son. His daughter Vinita D. Gupta serves as the Group President & CEO, based in the United States, and his son Nilesh Gupta is the Managing Director based in India. Gupta passed away on 26 June 2017 in Mumbai at the age of 79.

Devinder Pal

Devinder Pal was a distinguished figure in the Indian pharmaceutical industry, with a career spanning over five decades. Born on October 21, 1936, in Kohat, Punjab, India, he laid a strong educational foundation that propelled him into various leadership roles within the sector. His journey included significant positions at Warner-Lambert, Elder Pharmaceuticals, and ultimately, the establishment of his own consultancy, Catalyst Pharma Consult. ​

At Warner-Lambert, a company known for its diverse pharmaceutical and consumer healthcare products, Pal contributed to the organization's growth and innovation. His tenure there was marked by strategic initiatives that enhanced the company's market presence. Following this, he played a pivotal role at Elder Pharmaceuticals, further solidifying his reputation as a leader capable of steering companies toward success in the competitive pharmaceutical landscape.​

In 1985, Pal became a certified trainer for Warner-Lambert's leadership program, reflecting his commitment to fostering talent and leadership within the industry. His expertise and dedication were recognized by several prestigious awards:​

Fellowship of the Indian Pharmaceutical Association (1994): This honor acknowledged his significant contributions to the advancement of the pharmaceutical profession in India.​

Pharma Excellence Professional Award (2000): Presented by Pharma Business and Technology, India, this award celebrated his exceptional professional achievements in the pharmaceutical sector.​

Eminent Pharmacist Award (2003): This accolade recognized his outstanding contributions to the field of pharmacy, underscoring his dedication and impact on the industry.​

Pal's enduring commitment to the pharmaceutical industry continues to influence and inspire professionals and organizations within the sector. His legacy is further cemented by the Indian Pharmaceutical Association's establishment of the "IPA – Devinder Pal National Elocution Competition," aimed at fostering communication skills among pharmacy students. ​

Devinder Pal's journey reflects a legacy of leadership, innovation, and unwavering dedication to the advancement of the pharmaceutical industry. His contributions have left an indelible mark, inspiring future generations of professionals in the field.

Dilip Girdharlal Shah

Dilip Girdharlal Shah, affectionately known as DG Shah, was a pioneering figure in India's pharmaceutical industry, renowned for his advocacy of generic medicines and his instrumental role in shaping public health policies. Born in 1941, Shah was part of the inaugural graduating class of the Indian Institute of Management, Ahmedabad (IIMA) in 1966, where he met his future wife, Smita Dalal, marking the institute's first matrimonial alliance. ​

Shah commenced his professional journey with Pfizer in 1967, dedicating three decades to the company and ascending to the position of Commercial Director and board member for Pfizer India. In 1999, recognizing the need for a unified voice for domestic pharmaceutical companies, he founded the Indian Pharmaceutical Alliance (IPA). Under his leadership, the IPA championed the cause of generic drugs and opposed stringent intellectual property rights that could hinder access to affordable medicines. The alliance grew to encompass 24 leading Indian pharmaceutical companies, collectively representing a significant portion of the domestic market and exports. ​

Beyond the IPA, Shah established the Vision Consulting Group, offering expertise in public policy, strategy, and planning. He served in various advisory capacities, including as Chair of the International Generic Pharmaceutical Alliance (IGPA) for two terms and as a director for several pharmaceutical companies. His contributions were pivotal in shaping India's patent laws to favor affordable medicines while aligning with international agreements. ​

Shah's legacy continues through the "DG Shah Award for Best Public Policy Paper," instituted posthumously at IIMA to honor his immense contributions to public policy. His life's work significantly bolstered India's position as a global leader in generic medicines, ensuring access to affordable healthcare for millions worldwide.

Dr. Girish Sahni

Dr. Girish Sahni (1956 – August 19, 2024) was a distinguished Indian scientist renowned for his significant contributions to protein engineering, molecular biology, biotechnology, and enzymology. Born on March 2, 1956, he completed his Ph.D. at the Indian Institute of Science (IISc), Bangalore, in 1984. His research primarily focused on protein cardiovascular drugs, especially 'clot busters,' and their mechanisms within the human body. ​

Dr. Sahni began his career at the CSIR-Institute of Microbial Technology (IMTECH) in Chandigarh in 1991, ascending to the position of Director in 2005. In 2015, he was appointed Director General of the Council of Scientific and Industrial Research (CSIR) and Secretary of the Department of Scientific and Industrial Research (DSIR), roles he held until 2018. During his tenure, he emphasized translational research and fostered collaborations between scientific institutions and industry. ​

One of his notable achievements was the development of a clot-specific streptokinase, a breakthrough in cardiovascular treatment. In 2006, the licensing rights for this drug were acquired by Nostrum Pharmaceuticals in New Jersey, USA, marking a significant milestone in Indian academia's technology transfers. ​

Dr. Sahni was elected as a Fellow of the Indian Academy of Sciences in 2001, reflecting his esteemed status in the scientific community. His legacy continues to inspire advancements in biotechnology and protein engineering, with his work having a lasting impact on cardiovascular treatments and scientific research in India.

Dr. Kallam Anji Reddy

Dr. Kallam Anji Reddy (10 August 1941 – 15 March 2013) was a pioneering Indian entrepreneur and scientist who significantly impacted the global pharmaceutical industry. Born in Tadepalli, Andhra Pradesh, he completed his Bachelor of Science degree from A.C. College in Guntur in 1958 and later earned a B.Sc. (Tech) in Pharmaceuticals and Fine Chemicals from the University Department of Chemical Technology, Mumbai. He further pursued a Ph.D. in chemical engineering from the National Chemical Laboratory, Pune, in 1969. ​

In 1984, Dr. Reddy founded Dr. Reddy's Laboratories, transforming it into a global pharmaceutical powerhouse renowned for its innovative approaches to drug development and commitment to affordable healthcare. His leadership propelled the company to international markets, making significant strides in both generic and proprietary medicine sectors. ​

Dr. Reddy's contributions extended beyond his company. In 1996, he established the Dr. Reddy's Foundation, aiming to provide quality education and skill development to underprivileged youth, thereby enhancing their employment prospects. His dedication to social causes reflected his belief in inclusive growth and societal well-being.​

Throughout his illustrious career, Dr. Reddy received several prestigious honors, including the Padma Shri in 2001 and the Padma Bhushan in 2011, recognizing his invaluable contributions to the Indian pharmaceutical industry. In 2012, he was honored with the Lifetime Achievement in Health Award at the Asian Voice Political and Public Life Awards in Britain for his unwavering commitment to medical research and improving lives. His legacy continues to inspire innovation and social responsibility within the pharmaceutical sector.

Dr. Nitya Anand

Dr. Nitya Anand (1 January 1925 – 27 January 2024) was a distinguished Indian medicinal chemist renowned for his significant contributions to drug research and development. Born in Lyallpur, Punjab Province (now Faisalabad, Pakistan), he pursued higher education in chemistry, earning a Master's degree from St. Stephen's College in 1945 and a Ph.D. in organic chemistry from the Institute of Chemical Technology in Mumbai in 1948. He furthered his studies with a second Ph.D. from St. John's College, Cambridge University, and conducted post-doctoral research at Harvard Medical School in 1958. ​

In 1951, Dr. Anand joined the Central Drug Research Institute (CDRI) in Lucknow, where he served as the director from 1974 to 1984. His tenure at CDRI was marked by groundbreaking work, including the development of 'Centchroman' (branded as 'Saheli'), the world's first non-steroidal, non-hormonal, once-a-week oral contraceptive. This innovative drug, incorporated into India's National Family Planning Programme in 2016, offered a safer contraceptive option and represented a significant advancement in the field. ​

Dr. Anand's research interests centered on the design, discovery, and development of new drugs using synthetic chemistry approaches, focusing on drug-receptor interactions and metabolism. He published over 400 research articles, held more than 130 patents, and co-authored the book "Art in Organic Synthesis" with Jasjit S. Bindra in 1969. His expertise and leadership extended beyond CDRI; he served as chairman of the Ranbaxy Science Foundation and was a fellow of the Indian National Science Academy. ​

In recognition of his outstanding contributions to science and medicine, Dr. Anand was awarded the Padma Shri by the Government of India in 2012. His legacy continues through his work and the inspiration he provided to future generations of scientists. Notably, his daughter, Dr. Sonia Nityanand, has followed in his illustrious footsteps, serving as the Vice-Chancellor of King George's Medical University and also being honored with the Padma Shri in 2025. ​

Dr. Nitya Anand's pioneering efforts have left an indelible mark on India's pharmaceutical industry, exemplifying a lifelong commitment to scientific excellence and innovation.​

Dr. S.K. Punshi

Dr. S.K. Punshi is a distinguished Indian physician renowned for his expertise in dermatology, particularly in the treatment of vitiligo (leucoderma). He holds an MBBS from Indore and a DDV from Bombay, along with fellowships from FIMS and FDS (London). His clinic is located at Rajkamal Chowk, Amravati, Maharashtra. ​

Dr. Punshi's pioneering work includes the introduction of placental extract therapy for vitiligo, a significant advancement in dermatological treatments. His research is widely cited in various dermatology journals and books, reflecting his substantial contributions to the field. ​
bhagatkanwarram.com

Beyond his clinical practice, Dr. Punshi has been actively involved in social initiatives. Over the past 25 years in Amravati, he has participated in numerous diagnostic camps organized by the Indian Medical Association (IMA), Jaycees, Lions Club, and other social organizations, providing free examinations to thousands of patients. ​

Dr. Punshi has also contributed to public awareness through media engagements. He has delivered talks on "Leucoderma and Society" on All India Radio's Nagpur Station and was interviewed by Bombay Doordarshan in a national Hindi program discussing leucoderma. Despite his numerous achievements, Dr. Punshi remains humble, attributing his work to divine will and maintaining a holistic approach to life. ​

In summary, Dr. S.K. Punshi is a dedicated physician whose innovative treatments, community service, and public education efforts have significantly impacted the field of dermatology and patient care in India.

Dr. Muhammed Majeed

Dr. Muhammed Majeed (September 25, 1948 – March 13, 2024) was a pioneering scientist, entrepreneur, and philanthropist who made significant contributions to the nutraceutical and cosmeceutical industries. Born in Kerala, India, he pursued higher education in the United States, earning a Master's degree in Industrial Pharmacy from Long Island University and a Ph.D. in Industrial Chemistry. His academic background laid a strong foundation for his future endeavors in integrating traditional Ayurvedic knowledge with modern scientific research.​

In 1988, Dr. Majeed founded Sabinsa Corporation in the United States, focusing on the research and development of standardized herbal extracts and fine chemicals. His vision was to bring the rich heritage of Indian Ayurveda to the global stage through scientifically validated products. In 1991, he established Sami Labs Limited (now known as Sami-Sabinsa Group Limited) in Bengaluru, India, serving as a research and manufacturing hub. Under his leadership, the company expanded to operate seven manufacturing facilities and employed over 1,400 individuals, including more than 120 senior scientists dedicated to exploring the mechanisms of action and physiological effects of herbs. ​

Dr. Majeed's innovative approach led to the development of numerous patented products that bridged the gap between traditional herbal medicine and contemporary pharmaceutical needs. His commitment to quality and efficacy earned him several prestigious awards. In 2023, he was honored with the Lifetime Achievement Award at the 1st Kerala Pharmaceutical Congress, recognizing his invaluable contributions to shaping the Indian nutraceuticals industry and promoting preventive healthcare. Posthumously, in June 2024, he received the Times Business Awards Lifetime Achievement Award for his exemplary contributions to nutraceuticals, cosmeceuticals, and philanthropy. ​

Beyond his business accomplishments, Dr. Majeed was deeply committed to philanthropy, focusing on education and healthcare initiatives in India. He established the Dr. Majeed Foundation to support various charitable activities, reflecting his belief in giving back to society and enriching human life. His legacy continues through the ongoing work of the Sami-Sabinsa Group and the numerous lives touched by his philanthropic efforts.

Suresh Jadhav

Suresh Jadhav (1948/49 – 7 December 2021) was an Indian biotechnology executive and a key member of the Indian vaccine manufacturing industry. At the Serum Institute of India (SII) he led the development and introduction of the Meningococcal A conjugate vaccine to Sub-Saharan Africa and the production of the COVID-19 vaccine at SII, including the ones marketed as Covishield.

Jadhav was a member of the board of the GAVI vaccine alliance, and a member of the Indian government's expert committee on vaccines and other biologicals and a member of the Indian Pharmacopoeia Commission.

Jadhav was born in a village in Vidarbha in the eastern part of the Indian state of Maharashtra.[2] He completed his master's degree in pharmacy and later obtained a PhD from the Nagpur University.

He started his career in 1970 with a research fellowship at the Council of Scientific and Industrial Research (CSIR) before moving to the academia and teaching at the Department of Pharmaceutical Sciences, Nagpur, SNDT women's university, and the Haffkine Institute in Bombay.

Jadhav joined the Serum Institute of India (SII) in 1979, where he was responsible for manufacturing, laboratory and clinical practices, and quality control. He has been recognized as one of the contributors to SII being established as the world's largest vaccine manufacturer in the world. He became an executive director at the institute in 1992 and was responsible for manufacturing and quality control. He set up the institute's manufacturing facilities in Manjri near Pune. During his time at the SII, he led the development and introduction of the Meningococcal A conjugate vaccine to Sub-Saharan Africa. He also contributed to SII's acquisition of Bilthoven Biologicals in the Netherlands.

Jadhav's actions contributed to SII securing the World Health Organization accreditation for various vaccines enabling the company to export its vaccines to governments and health organizations across 140 countries. He was also a contributor to the Expanded Program on Immunization and had driven the partnership between the Bill and Melinda Gates Foundation and SII. Jadhav was also a member of the leadership team that worked on producing the COVID-19 vaccine at SII, including the ones marketed as Covishield.

Jadhav was also a member of various professional bodies and committees including the WHO committees relating to vaccine policy, reference standards, testing and validation studies. He was the president of the Developing Countries Vaccine Manufacturers Network, an alliance of vaccine manufacturers from developing countries, between 2004 and 2008. He was also a member of the board of GAVI vaccine alliance and was a member of its program and policy committee. He was also a member of the European Vaccine Institute and was a member of the Indian government's expert committee on vaccines and other biologicals and a member of the Indian Pharmacopoeia Commission. He was the co-chairman of the Confederation of Indian Industry's national committee on biotechnology for 2019–20.

Mr. B N Thakore

He was Quality Control Manager at Pfizer Ltd. & later promoted as “Compliance Head” before retirement from Pfizer.

After retirement he founded his own Co. called Morris Lab at Ankleshwar.

He was IPA President from 1984-86.
Before that he was very much involved with IPA in different capacities.
He along with other members established strong foundation of IPA.
He was actively involved in Indian Pharmacopeia - 95 version, monograph amendments.

G.C. Surana

G.C. Surana was a visionary entrepreneur and the founder of Micro Labs Limited, a prominent Indian pharmaceutical company. His journey in the pharmaceutical industry began with his association with a pharmaceutical distributor in Bangalore, which laid the foundation for his future endeavors. In 1973, he established Micro Labs in Chennai, leveraging his extensive experience and insight into the industry's potential. ​

Under Surana's leadership, Micro Labs expanded its footprint across India, establishing 14 state-of-the-art manufacturing facilities and three research and development centers employing over 300 dedicated scientists. The company's growth was further propelled by a robust sales team of more than 5,000 medical representatives, reaching over 250,000 doctors and 180,000 pharmacies nationwide. This strategic expansion positioned Micro Labs among the top pharmaceutical companies in India, ranking 10th in prescriptions and 20th in sales in the local market. ​

Surana's legacy is also reflected in his family's continued involvement in the business. His sons, Dilip Surana and Anand Surana, took over the company's operations in the 1980s and 1990s, respectively. Dilip currently serves as the Chairman and Managing Director, while Anand holds the position of Director. Their leadership has been instrumental in steering Micro Labs toward further growth and innovation, maintaining the visionary path laid by their father. ​

Beyond his business acumen, G.C. Surana was known for his commitment to quality and affordable healthcare. His dedication to excellence not only established Micro Labs as a reputable pharmaceutical company but also contributed significantly to the accessibility of essential medicines in India and beyond. Surana's entrepreneurial spirit and commitment to societal well-being continue to inspire and guide the company's ethos and operations.

G.C. Burman

Gyan Chand (G.C.) Burman was a pivotal figure in the history of Dabur India Limited, one of India's leading consumer goods companies known for its Ayurvedic products. As the Vice-Chairman and Managing Director, he played a significant role in steering the company towards growth and diversification. Under his leadership, Dabur expanded its product range and solidified its presence in both domestic and international markets.​

G.C. Burman passed away on September 7, 2001, due to a heart attack. His death marked the end of an era for the company, but his legacy continued through the next generation of the Burman family. Following his demise, his son, Amit Burman, joined the Dabur India board, increasing the number of Burman family members on the board from five to six. This transition ensured that the company's leadership remained within the family, maintaining the vision and values established by its founders.​

Today, Dabur India Limited stands as a testament to the Burman family's dedication and strategic vision. The company has evolved into a global leader in Ayurvedic and natural products, offering a wide range of items from health supplements to personal care products. The foundation laid by G.C. Burman and his predecessors has been instrumental in shaping Dabur's journey, reflecting a legacy of innovation, resilience, and commitment to quality.

Gracias Saldanha

Gracias Saldanha (1938 – 21 July 2012) was an Indian businessman and the founder of Glenmark Pharmaceuticals, a leading entity in the pharmaceutical industry. Born in Saligão, Goa, Saldanha pursued higher education in science, earning a master's degree from Bombay University. Before establishing his own venture, he accumulated over 12 years of experience working with various pharmaceutical companies, which laid the foundation for his entrepreneurial journey. ​

In 1977, Saldanha founded Glenmark Pharmaceuticals, naming the company after his two sons, Glenn and Mark. The company began as a manufacturer of generic drugs and active pharmaceutical ingredients, initially serving markets in India, Russia, and Africa. Under his leadership, Glenmark expanded its global footprint and diversified its product offerings, evolving into a significant player in the pharmaceutical sector. ​

Saldanha's commitment to innovation and quality propelled Glenmark's growth. He remained actively involved in the company's operations for over three decades, retiring as Chairman and Non-Executive Director in 2011. His legacy continues through his sons: Glenn Saldanha, who currently serves as the Managing Director and Chairman of Glenmark Pharmaceuticals, and Mark Saldanha, the owner and CEO of
Gracias Saldanha passed away on 21 July 2012 in Mumbai, Maharashtra, leaving behind a legacy of entrepreneurial spirit and significant contributions to the pharmaceutical industry. ​

Gracias Saldanha, the founder of Glenmark Pharmaceuticals, received several accolades during his illustrious career. Notably, in 2010, he was honored as the "Forbes Asia Businessman of the Year," recognizing his significant contributions to the pharmaceutical industry. ​
goansw.org

In 2011, Saldanha was listed at the 69th position on Forbes's list of Indian billionaires, with an estimated net worth of $805 million, reflecting his success and impact in the business world. ​
StartupTalky

His leadership also led Glenmark Pharmaceuticals to receive industry accolades, including the "SCRIP Award" for 'Best Company in Emerging Markets,' further cementing his legacy in the global.

Indravadan Ambalal Modi

Indravadan Ambalal Modi (18 February 1926 – 26 November 2012) was a pioneering Indian industrialist, renowned for his substantial contributions to the pharmaceutical sector. Born in Hansot, Bharuch district, Gujarat, he earned the moniker "Medicine Man of India" due to his relentless pursuit of making healthcare accessible and affordable. ​

Modi's commitment to ethical business practices and innovation was evident throughout his career. He emphasized the importance of clean and ethical practices, instilling these values within his company. His strategic decisions, particularly significant investments in research and development, led to the introduction of groundbreaking products like Polycap for heart disease prevention and Risorine for tuberculosis treatment. ​

Beyond his corporate achievements, Modi was deeply committed to philanthropy. Motivated by personal loss, he established the Kakaba and Kala-Budh Public Charitable Trust, under which he inaugurated a 30-bed hospital in Hansot to provide modern healthcare to underserved populations at reduced costs. ​

Modi's exemplary contributions garnered numerous accolades, including the Lifetime Achievement Award from the Gujarat Chamber of Commerce and Industry in 2005, the Express Pharma Pulse Lifetime Achievement Award, and the Indian Pharmaceutical Association's Ramanbhai Patel Foundation Lifetime Achievement Award. His enduring legacy continues to inspire advancements in India's pharmaceutical industry, reflecting his unwavering commitment to healthcare and societal well-being.

Jagdish Kantisarup Saxena

Jagdish Kantisarup Saxena was an influential figure in India's pharmaceutical industry, best known as the founder of Elder Pharmaceuticals. His journey from an employee to a successful entrepreneur is both inspiring and instructive.​

Saxena's entrepreneurial journey began unexpectedly. After the pharmaceutical division of his employer in Delhi shut down, he chose to start his own venture, leading to the establishment of Elder Pharmaceuticals in 1989. Under his leadership, the company flourished, becoming a significant player in the pharmaceutical sector. ​

Beyond his business endeavors, Saxena was a family man. He is survived by his wife, Sneh, and their three children: sons Alok and Anuj, and daughter Shalini. His son, Anuj Saxena, is a multifaceted personality known for his roles as an actor, producer, businessman, and restaurateur. ​
StarsUnfolded

Saxena's legacy is a testament to resilience and vision. His journey underscores the impact of seizing unforeseen opportunities and transforming challenges into successful ventures.

Krishan Kumar Arora

Mr. Krishan Kumar Aurora, a distinguished figure in the Indian pharmaceutical industry, passed away on December 23, 2024, at the age of 88. His career, spanning over six decades, was marked by transformative leadership and significant contributions to healthcare.​

Mr. Aurora began his professional journey as an accountant with A.F. Ferguson & Co., before moving on to Boots Pure Drug Co. (India) Ltd. In 1961, he joined Smith Kline & French (India) Ltd., where he ascended to the position of Managing Director and later became the International Vice President for Southeast Asia. His tenure at Smith Kline & French showcased his adeptness in navigating complex markets and his commitment to pharmaceutical excellence.​

In 1990, Mr. Aurora took over Pharmed Limited, transforming it into a trusted and respected name in the Indian pharmaceutical industry. Under his stewardship, Pharmed and the BioPlus Group became synonymous with innovation, quality, and excellence, earning accolades from healthcare providers. ​

Beyond his corporate achievements, Mr. Aurora played pivotal roles in industry organizations. As President of the Bangalore Chamber of Industry and Commerce (1988-89), he spearheaded significant initiatives, including establishing the Chamber’s first office in Bangalore and advocating for industrial reliefs on taxes and levies for captive power generation. In 2023, the Karnataka Drugs & Pharmaceuticals Manufacturers Association honored his unparalleled contributions to the pharmaceutical industry, celebrating his unwavering dedication and relentless pursuit of excellence.

CL Kaul

He was born on October 10, 1936. He graduated with a B. Sc. from the Panjab University, Chandigarh in 1956 and a B. Pharm. from the prestigious L. M. College of Pharmacy in Ahmedabad in 1959. Subsequently, he completed his Doctor of Philosophy from the University of Glasgow, Scotland in 1964. After a brief Postdoctoral work at the University of Glasgow in 1964, he returned to India and started his career in the Ciba-Geigy Research Centre in Bombay in 1965 and served in various capacities till 1979. He then joined the Boots Pharmaceuticals, Bombay as a research manager in 1979, became the director, research in 1984 and then the director, research and development in 1987. He joined the National Institute of Pharmaceutical Education and Research (NIPER) as the Founder Director on September 1, 1994, and was involved in shaping that institute to international repute for a decade till his retirement in 2004. Dr. Kaul’s research over a period of 4 decades involved discovery and pre-clinical development of new drugs, development of pharmaceutical formulations that included stability evaluations and bioavailability studies. Many new chemical entities under his able supervision reached different phases of clinical development and two of which have received approval for marketing. Dr. Kaul has published around 150 research papers in peered review journals, 20 patents and 4 book chapters. Dr. Kaul was very active professionally and contributed immensely to the pharmaceutical profession through the Indian Pharmaceutical Association (IPA). Dr. Kaul's contributions to IPA were phenomenal. He was the Hon. Gen. Secretary during 1988-92, a Vice President of IPA during 1992-94 and the President of IPA during 1994- 96. Dr. Kaul received the prestigious IPA Fellowship in 2000 followed by the coveted Eminent Pharmacist Award in 2002. Dr. Kaul initially served as an editorial board member of IJPS, then as the associate editor from 1986-92. He was the editor of IJPS during 1992-96. In 1996 Dr. Kaul relinquished the editor position and served the journal as an advisory board member till his untimely demise. We at IJPS, condole the sad demise of Dr. C. L. Kaul and pay our respects and tribute to Dr. C. L. Kaul for his stupendous contribution to the pharmacy profession.

Mahadeva Lal Schroff

Prof. Mahadeva Lal Schroff is regarded as India's founder of pharmacy. He attained this distinction as a result of his accomplishments, which included steering India's pharmaceutical sector and educational system in the proper direction. Furthermore, despite the fact that he was not even a professional pharmacist, he had a huge influence on the pharmaceutical sector.

Prof. Mahadeva Lal Schroff is known as the Father of Pharmacy Education in India because he steered the field of pharmacy in the correct direction and inspired several generations of pharmacists. He wasn't a qualified pharmacist, but his contributions to the industry are many, and he fostered the field to provide opportunities for future pharmacists. Throughout his life and profession, he faced several barriers and major problems.

Prof. Mahadeva Lal Schroff was born in the Bihar city of Darbhanga on March 6, 1902. He finished his education at Bhagalpur (Bihar) and passed his intermediate test in 1920. Following that, he enrolled in the Engineering College at Banaras Hindu University (BHU) in Varanasi, India. Prof. Schroff was ordered to leave the institution in 1921 after speaking out against the then-principal, Charles A. King. Prof. Schroff left India after graduating from engineering school and spent time in China, Japan, and America. He earned his UG degree in arts with honors in chemistry in 1925 and his PG degree in chemistry and microbiology from the Massachusetts Institute of Technology (MIT) in 1927.

Prof. Mahadeva Lal Schroff, properly referred to as the Father of Pharmacy Education in India, passed away on August 25, 1971, and he surely remains an inspiration to all pharmacists working in this nation, regardless of their branches or responsibilities. Prof. Schroff, who was not qualified as a pharmacist, guided not just pharmaceutical education but also the Indian industry with his aptitude, comprehension, talent, and broad vision.

The following are some of the things which are founded by Prof. Mahadeva Lal Schroff-

Indian Pharma Association (1935 as the U.P. Pharma Association and 1939 as the Indian Pharmacy Association).
Indian Journal of Pharmacists (1945).
Bhaishaj Patrika in Hindi (1980).
Bheshjayan (1968).
Indian Pharmaceutical Congress (1968).
President of various State Pharmacist Associations (Bengal, Bihar).
President of the Pharmacy Council of India (1954-1959).

His work, "The History of Indian Pharmacy," is a classic treatise that unfolds the numerous features of pharmacy practice in ancient and medieval India, which have roots and significance even in current pharmacy in our nation. Prof. Mahadeva Lal Schroff's life inspires us to work hard, be sincere in our intentions, and serve the homeland. As the pioneer who lighted the fire of pharmaceutical education in the country, he will remain an inspiration to Indian pharmacists.

Khwaja Abdul Hamied

Khwaja Abdul Hamied (31 October 1898 – 23 June 1972) was an Indian industrial and pharmaceutical chemist who founded Cipla, India's oldest pharmaceutical company in 1935. His son, Yusuf Hamied headed the company after him for the next 52 years. Khwaja Abdul Hamied was active in the Indian independence movement and a champion of composite nationalism. Early life and background - Hamied was born in Aligarh, to Khwaja Abdul Ali, an advocate, and Masood Jahan Begum. Through his father, he was descended from the Sufi saint Khwaja Ahrar of iran (Uzbekistan), while on his mother's side, he was descended from Shah Shuja, the last Durrani king of Afghanistan. His paternal great-uncle was the noted reformer Sayyid Ahmad Khan he was also the grandnephew of Khwaja Muhammad Yusuf and a nephew to Abdul Majeed Khwaja. Education - After matriculating from Islamia High School, Etawah, distinguishing himself in mathematics, Hamied completed his Intermediate in Science from Agra College in 1917. Having decided to become a chemist, he then spent a year at a Madras trade school studying leather technology before enrolling at Muir Central College in Allahabad, from which he completed his B.Sc. in chemistry in 1920. While at the college, he became a favourite student of Nil Ratan Dhar, a distinguished inorganic chemist under whom he studied for a master's degree. He graduated from Allahabad University in Allahabad, Uttar Pradesh and held M.A. and PhD degrees from the Humboldt University of Berlin in Germany. He was a disciple of M.K. Gandhi and former founder professor along with Zakir Husain of the Jamia Milia Islamia in Aligarh, now based in Delhi. Career - Hamied's family raised money to send him to study chemistry in England, during British rule, in 1924. Instead, he changed ships and went to Germany, then the world's leader in chemicals. On a Berlin lake, he met a Lithuanian Jewish socialist, whom he married. They fled as the Nazis rose to power in Germany. Chemical, Industrial and Pharmaceutical Laboratories, Cipla was founded in 1935 with an initial capital of Rs. 2 lakhs. The company commenced production in 1937 making it the oldest pharmaceutical company in India. His eldest son Yusuf Hamied, who did study chemistry in England, is now Chairman of Cipla. Yusuf still refers to his chemistry notebooks from Cambridge. Apart from conceiving the idea of establishing a National Chemical Laboratory and making it a reality, Dr Khwaja Hamied floated the idea and conceptualized the establishment of the Council of Scientific and Industrial Research (CSIR) as an umbrella organization to run a clutch of laboratories. He remained a Member of the Governing Body of the CSIR right from its inception till the very last. During the last four decades of his life, he played an important role in raising the pharmaceutical and chemical industry standards in India to an extraordinarily high level through founding the firm Cipla. Dr. Hamied was an honorary professor and a member of the executive council of the Aligarh Muslim University, member of the Senate of Bombay University and a fellow of the Royal Institute of Chemistry, UK. He was also a member of the Bombay Legislative Council from 1937 to 1962, refusing the offer of becoming a Muslim Minister in the cabinet in Bombay. Hamied also served as Sheriff of Bombay. Dr Khwaja Abdul Hamied died in 1972 after a brief illness.

Prof. Harkishan Singh

Professor Harkishan Singh, (25th November 1928 - 20th March 2020) was Professor Emeritus at the Panjab University (Chandigarh, India), is a well recognized pharmaceutical academic, medicinal chemistry researcher and a science historian. He has experience of over half a century to his credit. He has worked at the Banaras Hindu University, University of Saugar and Punjab University in India, and abroad at the University of Maryland, University of Mississippi and the University of London. His scientific research has been in organic chemistry, medical chemistry and natural products. Nearly 50 master and doctoral theses have been completed under his supervision. There have been published 125 original scientific research papers. 14 patents have been obtained. His research group has been successful in designing a clinically useful drug candocuronium iodide (INN) (chandonium iodide, HS-310), which is a synthetic azasteroid. Dr Singh has lectured on his research at several of the institutions and conferences in India, United States of America, Canada, United Kingdom, Switzerland and China. He delivered invited lectures at the Harvard School of Medicine and at the International Symposium on Molecular Structure sponsored by the International Union of Crystallography at Beijing. As a science historian Professor Singh has examined the history of pharmaceutical developments in India of the nineteenth and twentieth centuries. His history research studies have been on pharmacopoeias and formularies, pharmaceutical education, pharmacy practice, biographies of pharmaceutical luminaries, and pharmaceutical journalism. He has published over eighty articles. All told his total publications come to well over 350, including eighteen books. Selected publications are listed later. Professor Singh has been on many academic, scientific, professional and governmental bodies. He was a member of the Committee on International Education of Medicinal Chemists of the International Union of Pure and Applied Chemistry, which prepared the Report on the International Education of Medicinal Chemists (IUPAC Technical Reports Number 13; 1974). His affiliations with several scientific and professional organizations include emeritus membership of the American Chemical Society, life memberships of the Indian Pharmaceutical Association and Association of Pharmaceutical Teachers of India, and memberships of the American Institute of History of Pharmacy and British Society for History of Pharmacy. Professor Harkishan Singh was a recipient of several scientific and professional awards and recognitions. He has been a National Fellow of the University Grants Commission, New Delhi. He has been General President of the Indian Pharmaceutical Congress. He received Eminent Pharmacist Award of the Indian Pharmaceutical Association. Lifetime achievement awards have been conferred on him by several bodies; the recent one is the Lifetime Achievement Award by the Punjab Academy of Sciences. Dr Singh's standing as historian has been recognized through his election to the Academie Internationale d'Histoire de la Pharmacie. The University of the Sciences in Philadelphia conferred upon Professor Harkishan Singh the degree of Doctor of Science (Honoris Causa) in recognition of his distinguished academic career and outstanding contributions to scientific research in organic and medicinal chemistry and the history of pharmacy. Candocuronium (Chandonium), A Neuromuscular Blocker Discovery The research papers and reviews marked with asterisk under Medicinal Chemistry and Allied Fields refer to synthetic azasteroidal neuromuscular blockers and related aspects. A new neuromuscular blocker, initially named as Chandonium Iodide, was designed and synthesized by the research group of Professor Harkishan Singh at the Panjab University, Chandigarh. The pharmacological testing was carried out at the University at Strathclyde. The toxicity studies at the Central Drug Research Institute, Lucknow, did not reveal any adverse effects. The clinical studies were also successfully completed through the CDRI. The proceedings of the symposium on the clinical testing on Chandonium Iodide were published in the Journal of Anaesthesiology and Clinical Pharmacology, 10, 109-151 (1994). The drug was cleared by the Ministry of Health, Government of India, for manufacturing and clinical use. The World Health Organization gave to the drug the INN designation Candocuronium Iodide. The drug is a potent non-depolarizing neuromuscular blocker with short duration of action. The injections can be sterilized by autoclaving. The preparation can be stored at room temperature without any loss of activity.

Dr. Parvinder Singh

Dr. Parvinder Singh was a visionary leader who played a pivotal role in transforming Ranbaxy Laboratories into a global pharmaceutical powerhouse. Born into a family with business acumen, he pursued higher education in pharmacy, earning a master's degree from Washington State University and a Ph.D. from the University of Michigan. In 1967, he joined Ranbaxy, a company founded by his father, Bhai Mohan Singh, and quickly became instrumental in its evolution from a domestic enterprise to an international entity.

Throughout his illustrious career, Dr. Singh was recognized for his contributions to the pharmaceutical industry. He was instrumental in making Ranbaxy the first Indian pharmaceutical company to break into the U.S. and European markets with its generic drugs. His efforts in promoting research and development led to the establishment of state-of-the-art R&D facilities in India. Under his leadership, Ranbaxy received numerous global regulatory approvals, including those from the U.S. Food and Drug Administration (FDA), making it a credible player in the international market.

Dr. Singh's leadership style was characterized by a blend of traditional values and modern management practices, fostering a culture of excellence and integrity within the organization. He was a key advocate for Indian pharmaceutical self-reliance and was instrumental in shaping policies that encouraged indigenous research and production. His contributions to the industry earned him respect among peers, and he was often regarded as a trailblazer who set high standards in corporate governance and ethical business practices.

Tragically, Dr. Parvinder Singh passed away in 1999, but his legacy endures. He is remembered not only for his business acumen but also for his commitment to ethical practices and corporate governance. His contributions laid the foundation for Ranbaxy's subsequent growth and have been a source of inspiration for future generations of business leaders in India.

Ramanbhai B. Patel

Ramanbhai B. Patel (19 August 1925 – 19 September 2001) was an influential Indian chemist and entrepreneur, best known for founding Cadila Laboratories, which evolved into one of India's leading pharmaceutical companies. Born in Kathor, South Gujarat, Patel pursued a degree in chemistry at Gujarat University's L.M. College of Pharmacy. He began his career as a lecturer before venturing into the pharmaceutical industry. ​

In 1952, Patel co-founded Cadila Laboratories with his school friend Indravadan Modi. Under his visionary leadership, the company made significant strides in the pharmaceutical sector. Notable achievements include the production of Isopar, a formulation of anti-tuberculosis drugs, in 1957, and Neuroxin-12, a single-vial mixture of vitamins B1, B6, and B12, in 1959. The firm also developed process technology for the anti-diabetic drug glibenclamide in 1973 and launched Dexona-20, a concentrated form of the anti-inflammatory drug dexamethasone, in 1977. ​

Patel's contributions to the pharmaceutical industry and education were widely recognized. He received several prestigious awards, including the President of India's Import Substitution Award in 1973, the Prof. M.L. Shroff Memorial National Award in 1987, the Glory of India Award in 1991 in Washington, the Grahak Suraksha Award in 1992, the Acharya Prafulla Chandra Ray Memorial Gold Medal in 1993, and the Eminent Pharmacist Award in 1994. In 2000, he was honored as the Gujarat Businessman of the Year. ​

Beyond his industrial achievements, Patel was committed to advancing pharmaceutical education, particularly in Gujarat's rural areas. His efforts led to the establishment of several reputed pharmacy colleges, making professional courses more accessible to students in smaller towns. In recognition of his lasting impact, the Indian Pharmaceutical Association, in collaboration with the Ramanbhai B. Patel Foundation, instituted the IRF Life Time Achievement Award in 2003 to honor senior pharmacists who have made noteworthy contributions to the field. ​

Patel's legacy continues through Cadila Healthcare, now known as Zydus Lifesciences, under the leadership of his son, Pankaj R. Patel. The company remains a testament to his vision of providing affordable, high-quality medicines, significantly contributing to the accessibility of healthcare in India and beyond.

Ranjit Shahani

Ranjit Shahani was a renowned leader in the pharmaceutical industry, best known for his role as the Former Vice-Chairman and Managing Director of Novartis India Ltd. He played a crucial role in shaping Novartis’ presence in India, leading the company through various regulatory and market challenges. Before joining Novartis in 1997, he had an illustrious career with major global corporations such as Roche and ICI Zeneca, where he held leadership roles in diverse industries, including petrochemicals, plastics, and healthcare. His experience across sectors gave him a broad perspective, which he applied effectively in the pharmaceutical space.

During his tenure at Novartis, Mr. Shahani was instrumental in handling one of the biggest patent disputes in Indian pharmaceutical history over the cancer drug Glivec. His calm and composed leadership during this high-stakes battle earned him significant respect within the industry. Beyond Novartis, he was actively involved in industry organizations, serving as President of the Organisation of Pharmaceutical Producers of India (OPPI) and President of the Swiss Indian Chamber of Commerce. He was also a key figure in shaping pharmaceutical policy and advocating for industry growth in India.

Apart from his corporate achievements, Mr. Shahani contributed significantly to various boards, including JB Chemicals & Pharmaceuticals, Hikal Ltd, and Ambuja Cements. His influence extended beyond pharmaceuticals into other industries, where his strategic guidance and leadership were highly valued. His expertise and business acumen made him a sought-after advisor for many organizations.

Ranjit Shahani passed away on March 9, 2024, at the age of 74, leaving behind a remarkable legacy. He was known not just for his business achievements but also for his mentorship, generosity, and ability to navigate complex industry landscapes. His contributions to the pharmaceutical sector in India were transformative, and his leadership continues to inspire professionals in the field.

Samprada Singh

Samprada Singh (1925 – 27 July 2019) was a pioneering Indian entrepreneur and founder of Alkem Laboratories, one of India's leading pharmaceutical companies. Born in Okri village, Jehanabad, Bihar, Singh graduated with a Bachelor of Commerce degree from Patna University. His initial venture into the pharmaceutical industry began in 1953 with a small chemist shop near Patna Medical College and Hospital. This modest beginning laid the foundation for his future endeavors in the pharmaceutical sector. ​
In 1973, Singh founded Alkem Laboratories in partnership with his younger brother, Basudeo Narayan Singh. Under his visionary leadership, Alkem expanded its operations globally, establishing a significant presence in Europe, Africa, the Asia Pacific, South America, and the United States. The company's growth was marked by its commitment to developing, manufacturing, and marketing high-quality pharmaceutical formulations and nutraceuticals. Singh's strategic direction and dedication were instrumental in positioning Alkem as a major player in the global pharmaceutical industry. ​

Throughout his illustrious career, Singh received numerous accolades recognizing his contributions to the pharmaceutical sector. In 2009, he was honored with the Lifetime Achievement Award at the Pharmaceutical Leadership Summit & Awards. In 2017, he received the Ernst and Young 'Entrepreneur of the Year in Healthcare and Life Sciences' award. That same year, Forbes India ranked him as the 43rd richest individual in the country, with an estimated net worth of $3.3 billion. ​

Singh's journey from a small chemist shop to leading a global pharmaceutical giant exemplifies entrepreneurial spirit and dedication. His legacy continues to inspire future generations in the pharmaceutical industry. Singh passed away on 27 July 2019 at the age of 94, leaving behind a lasting impact on the industry he helped shape.

Sanjeev I. Dani

Sanjeev I. Dani was a distinguished figure in the pharmaceutical industry, renowned for his extensive contributions over a career spanning several decades. He held pivotal roles in major pharmaceutical companies, including a significant tenure at Ranbaxy Laboratories, where he managed various markets such as India, the Middle East, Asia Pacific, and Africa. ​

In August 2015, Mr. Dani joined Aurobindo Pharma as the Chief Operating Officer (COO) and Head of Formulations. In this capacity, he led the front-end operations of emerging markets and Europe, playing a crucial role in steering the company's strategic direction and operational excellence. ​

Tragically, on November 21, 2023, the pharmaceutical community mourned the loss of Mr. Dani. His passing marked a poignant moment for the industry, as he had been a driving force in shaping the pharmaceutical landscape through his leadership and vision. ​

Mr. Dani's legacy is characterized by his dedication to advancing the pharmaceutical sector, his strategic acumen, and his commitment to fostering growth in the markets he oversaw. His contributions have left an indelible mark on the industry, inspiring future generations of pharmaceutical professionals.

Mr. Upendra Madan Deshpande

Mr. Upendra Madan Deshpande, born on April 30, 1963, was a distinguished leader in the pharmaceutical industry, serving as the Director of Milan Laboratories (India) Pvt. Ltd. since March 26, 2003. ​

Under his guidance, Milan Laboratories expanded its global footprint, exporting pharmaceutical formulations to over 43 countries and securing more than 300 marketing authorizations worldwide. The company's facilities achieved approvals from stringent regulatory authorities, including the UK-MHRA and South Africa's MCC, reflecting Mr. Deshpande's commitment to maintaining high-quality standards.​

Mr. Deshpande's leadership was instrumental in Milan Laboratories' recognition as a Government Recognized Star Export House and its receipt of various awards for quality excellence and outstanding export performance. His dedication to innovation and excellence significantly contributed to the company's growth and success in the competitive pharmaceutical sector.​

Beyond his professional achievements, Mr. Deshpande was known for his joyfulness, generosity, and commitment to fitness. His sudden passing on March 8, 2025, due to a cardiac arrest, was a profound loss to all who knew him. His legacy continues to inspire those at Milan Laboratories and the broader pharmaceutical community. ​

Uttambhai Nathalal Mehta

Uttambhai Nathalal Mehta (1924 - 1998) was an Indian businessman and the founder and chairman of Torrent Group.

Early and personal life
Mehta was born in Mehmadpur, a small village in Palanpur district, India, in Gujarati Jain family. After finishing his primary education in Palanpur, moved to Mumbai, where he completed his B.Sc. from Wilson College, while staying at the Mahavir Jain Vidyalay hostel.

Mehta and his wife Shardaben, had four children, sons Sudhir and Samir, and daughters Meena and Nayna

Career
He started his career as a government servant in 1944. He worked as a medical representative for the pharmaceutical company Sandoz from 1945 to 1958.

Then in 1959 he took the path breaking decision to start his own firm Trinity Laboratories with a seed capital of just Rs 25,000. This organization began to manufacture special medicines. In 1968, Mehta began to market a medicine for treatment of mental diseases.

It was a big step at a time when only multinational companies manufactured specialty drugs, and subsequently Mehta went on to establish Torrent Laboratories in 1976. The company began marketing a number of drugs at competitive prices and soon made a name for itself. Today, Torrent is a large company engaged in the business of pharmaceutical goods and power generation.

Awards and recognition
He was conferred with numerous felicitations, including the ‘Business Man of the Year’ award in 1996-97 from the Government of India. Torrent has also won many awards for in manufacturing, exporting and marketing.

U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC) at Ahmedabad, Gujarat is named after him. Over the years, Torrent group has provided sizeable financial contribution, which has been used for constructing a 450-bedded facility. Apart from Hospital Infrastructure development, Torrent’s Patient Care Initiative Programme at UNMICRC has resulted in effective service delivery and better hospital management. The treatment is rendered to all patients, particularly the economically disadvantaged. Free Cardiac treatment is provided to Gujarat domiciled children and patients from the weaker strata

Vinay Thakur

Vinay Thakur, a pharmacist of repute who won a gold medal during his B Pharm and M Pharm and carried a rich industrial experience. Wanted to change the approach of quality of products produced at third party manufacturing locations. Realised this dream through his firm Mistair Pharma, setting a trend of uncompromising global pharmaceutical standards amongst TPMs. He would often say ' Cost is a fact, price is a policy and quality is the gospel reality. The team Mistair now treads the path of this philosophy.